Paragon, NIAID in Preclinical Drug Development Pact

Paragon Bioservices has received a multiple-award, indefinite-delivery, indefinite-quantity (IDIQ) contract to provide product development services for a variety of National Institute of Allergy and Infectious Diseases (NIAID) medical product development activities. The IDIQ mechanism will allow Paragon to compete within a contractor pool for task order awards up to $159 million.

Paragon is one of four awardees to receive the IDIQ valued up to $159 million, with a period of performance of up to 10 years. The award covers the development and introduction of new therapeutic products against a range of global infectious diseases. Under the contract, the company will develop manufacturing processes and analytical test methods and perform product characterization.

"Paragon Bioservices considers this award to be a significant honor which reflects the expertise and dedication of every Paragon employee," said Pete Buzy, president and chief executive officer, Paragon."Paragon is very excited to be working closely with NIAID on preclinical drug development. Over the next decade, Paragon will play an integral role by advancing research and development in the global vaccine market and public health."